History Says This Is Hands-Down the Best ETF to Buy if a Bear Market Is Coming

The article presents the Schwab U.S. Dividend Equity ETF (SCHD) as a defensive option if a bear market arrives in 2027, noting it outperformed the S&P 500 and Nasdaq-100 during the 2022 bear market. SCHD holds 102 stocks, with 20.7% in healthcare, 20.4% in consumer staples, 14.1% in energy and 9.23% in information technology; its annualized return since its October 2011 inception is about 13.1%. The piece cites higher bond yields, persistent inflation and AI-related borrowing as risks, while cautioning that past performance does not predict future returns.

Analysis

The defensive basket thesis is more a factor and valuation call than a reliable recession hedge. SCHD’s lower growth exposure may cushion an earnings-led selloff, but its dividend/value tilt can still lose value if real yields rise: higher-quality bond income competes with equity distributions, while valuation multiples on yield-sensitive stocks can compress. A slowdown driven by sticky inflation is especially awkward—input costs can pressure consumer-staples margins even as households trade down, and healthcare defensiveness does not remove product-cycle or patent risks for Merck & Co. (MRK). The Coca-Cola Company (KO) and Procter & Gamble (PG) may have pricing power, but the key test is whether volume and margins hold as pricing normalizes, not whether demand is nominally essential.

Near term, the hypothetical 2027 bear-market framing is not itself a catalyst; chasing defensive exposure after strong relative performance risks paying for insurance before it is needed. Over 1–3 months, watch real yields, inflation data, and earnings revisions for staples and pharma. Over 6–18 months, AI investment monetization—or disappointment—could determine whether market leadership broadens or defensive/value factors regain relative appeal. The contrarian risk is that investors overgeneralize from one bear-market episode: sector outcomes depend on the cause of the drawdown, starting valuations, and rate path. Verify current SCHD holdings, valuation, and sector weights before implementation; the article’s historical comparison does not establish future downside protection.

Key Decisions for Investors

• No need to rotate wholesale into SCHD solely on a forecast of a 2027 crash. If reducing equity beta, phase exposure in and compare SCHD’s valuation and yield with current Treasury yields; reassess if real yields rise while defensive earnings estimates weaken.
• Relative-value watch: consider a small SCHD-versus-Nasdaq-100 position only if earnings revisions deteriorate for growth leadership while defensive estimates remain stable. Define the thesis by relative performance and revisions, not by a calendar-date crash call; exit if growth earnings breadth improves or defensive revisions turn negative.
• For KO and PG, monitor organic volume, price/mix, gross-margin commentary, and foreign-exchange sensitivity; weakening volumes without margin recovery would falsify the presumed resilience. For MRK, track pipeline and patent-exposure updates rather than treating healthcare sector classification as protection.
• Catalyst checklist: inflation and real-yield direction, Fed communication, and company guidance. If inflation stays sticky and yields rise, dividend equities may not hedge; if yields fall alongside broad earnings downgrades, defensive cash flows could gain relative value.